Trump cracks down on H-1B that feeds Silicon Valley

April 4, 2017

Washington, Apr 4: The U.S. administration began to deliver on President Donald Trump's campaign promise to crack down on a work visa program that channels thousands of skilled overseas workers to companies across the technology industry.

trump3Fed up with a program it says favors foreign workers at the expense of Americans, the Trump administration rolled out a trio of policy shifts. The U.S. Citizenship and Immigration Services agency on Friday made it harder for companies to bring overseas tech workers to the U.S. using the H-1B work visa. On Monday, the agency issued a memo laying out new measures to combat what it called "fraud and abuse" in the program. The Justice Department also warned employers applying for the visas not to discriminate against U.S. workers.

Trump campaigned on a promise to overhaul the immigration system, calling for companies to hire more Americans instead of outsourcing jobs to countries with cheaper labor or bringing in lower-paid foreign workers. Silicon Valley's biggest tech companies, many of which were founded or run by immigrants, depend on H-1Bs and say efforts to thwart immigration threaten innovation, recruitment and startup formation. Trump's executive orders restricting travel from a handful of Muslim-majority nations led to unprecedented opposition from the industry.

But there's also broad recognition that reform is needed, given several high-profile examples where American employees have been replaced by lower-paid foreign workers through the program. Advocates for immigrants' rights also argue H-1B workers are easily exploited because their legal status is tied to a particular employer. The Economic Policy Institute estimated there were about 460,000 people working on H-1B visas in 2013.

This week's moves weren't the administration's first attempts to adjust the program. Last month, the immigration department suspended a system that expedited visa processing for certain skilled workers who paid extra. But people who have been pushing for reform had become frustrated in recent weeks that the Trump administration wasn't moving fast enough.

Outsourcing firms are considered the worst abusers of the system, an impression that the tech industry has been happy to encourage. Monday's USCIS announcement targets those firms, with the agency saying it will focus inspections on workplaces with the largest percentage of H-1B workers, and those with employees who do IT work for other companies. Shares of Cognizant Technology Solutions Corp., Infosys Ltd., Wipro Ltd. and Accenture Plc each slipped more than 1 percent on Monday.

Microsoft Corp., Facebook Inc., Alphabet Inc., Cognizant, Wipro and Accenture didn't respond to requests to comment. Infosys declined to comment, while Tata Consulting Services Ltd. said it has reduced use of high-skilled H-1B visas, while creating more U.S. IT services jobs.

The new guidelines released Friday require additional information for computer programmers applying for H-1B visas to prove the jobs are complicated and require more advanced knowledge and experience. It's effective immediately, so it will change how companies apply for the visas in an annual lottery process that begins Monday. The changes don't explicitly prohibit applications for a specific type of job. Instead, they bring more scrutiny to those for computer programmers doing the simplest jobs.

"This is a step in the right direction in terms of tightening up the eligibility," said Ron Hira, an associate professor at Howard University, who has done extensive research on the H-1B program. "You're going to have to beef up your argument for why you need this person."

Technology and outsourcing companies are the heaviest users of the H-1B visa, which is the largest program for temporary foreign workers in the U.S. by a wide margin. India-based outsourcing companies receive a disproportionate percentage of the visas and tend to pay lower salaries than U.S.-based tech firms. Employers sought H-1B visas for more than 13,000 computer programmers in 2016, citing an average salary of about $72,000, according to Bloomberg Intelligence analyst Caitlin Webber. About half of the visas sought last year were for computer-related positions, she said.

Computer programmers made up about 12 percent of all H-1B applications certified by the Department of Labor in 2015. Of those, 41 percent were for positions at the lowest wage level, defined as jobs requiring people to perform routine tasks that require them to exercise little judgment on their own. The guidelines issued Friday refer specifically to entry-level computer programmers, which the U.S. Department of Labor defines as those who write and test code to allow computer applications and software to work properly.

"This is not a change in policy on H-1B and H-1B1 eligibility in computer-related fields," CeCe Gwathmey, a spokeswoman for the immigration agency, said in an email, referencing the March 31 document. The memorandum rescinded a 17-year-old set of guidelines that "relied on obsolete information and had not been used as a standard" to decide on H-1B petitions for many years, she said.

Still, the administration hasn't thrown its lot in with any of the plans for broader changes to the program. Lawmakers from both parties have introduced several bills this year. One would replace the current random lottery with a system that gives priority to companies paying higher salaries. Another would explicitly prohibit companies from replacing qualified U.S. workers with H-1B workers.

Scott Corley, executive director Compete America, a coalition of employers that rely on high-skilled immigrants, said in a statement Monday that H-1B reform should be part of a broader re-assessment of the country's immigration priorities. "Our nation's outdated legal immigration system relies heavily on a single temporary visa category, the H-1B, to prove work authorization for every kind of high-skilled foreign professional we recruit," he said.

The result, said Corley: "Chaos, inefficiencies, and criticism."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 20,2020

Paris, Jul 20: Two coronavirus vaccine candidates have proven safe for humans and produced strong immune reactions among patients involved in separate clinical trials, doctors said on Monday.

The first trial among more than 1,000 adults in Britain found that the vaccine induced "strong antibody and T cell immune responses" against the novel coronavirus.

A separate trial in China involving more than 500 people showed most had developed widespread antibody immune response.

The studies, published in The Lancet medical journal, constitute a major step on the road towards a COVID-19 vaccine that is effective and safe for widespread use.

The authors of the studies said that they encountered few adverse side-effects from the vaccine candidates.

However, they cautioned that more research was needed, particularly among older adults, who are disproportionately at risk of dying of COVID-19.

Co-author Sarah Gilbert from the University of Oxford said the results "hold promise".

"If our vaccine is effective, it is a promising option as these types of vaccine can be manufactured at large scale."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 28,2020

More than one in six youths were jobless since the onset of the COVID-19 pandemic while those who remain employed have seen their working hours cut by 23 per cent, according to a report by the International Labour Organisation (ILO).

According to the 'ILO Monitor: COVID-19 and the world of work: 4th edition' published on Wednesday, youths are being disproportionately affected by the pandemic, and the substantial and rapid increase in youth unemployment seen since February is affecting young women more than young men, reports Xinhua news agency.

The pandemic is inflicting a triple shock on young people.

Not only is it destroying their employment, but it is also disrupting education and training, and placing major obstacles in the way of those seeking to enter the labour market or to move between jobs, said the report.

At 13.6 per cent, the youth unemployment rate in 2019 was already higher than any other group.

There were around 267 million young people not in employment, education or training worldwide.

"If we do not take significant and immediate action to improve their situation, the legacy of the virus could be with us for decades," said ILO Director-General Guy Ryder.

"If their talent and energy is sidelined by a lack of opportunity or skills, it will damage all our futures and make it much more difficult to re-build a better, post-COVID economy."

The report called for urgent, large-scale and targeted policy responses to support youth, including broad-based employment/training guarantee programs in developed countries, and employment-intensive programs and guarantees in low- and middle-income economies.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.